Welcome to our dedicated page for Esperion Therape news (Ticker: ESPR), a resource for investors and traders seeking the latest updates and insights on Esperion Therape stock.
Esperion Therapeutics Inc. (NASDAQ: ESPR) is a pharmaceutical company developing and commercializing oral cholesterol-lowering medications for patients with cardiovascular disease risk. The company's news flow reflects its position as a commercial-stage biotech navigating product launches, partnership expansions, and ongoing clinical evidence generation in the cardiovascular therapeutics market.
News from Esperion typically covers developments across several key areas. Regulatory and partnership milestones feature prominently as the company works with international partners to secure approvals and launch its products in new markets. These announcements track the global expansion of NEXLETOL and NEXLIZET beyond the United States through licensing relationships with regional pharmaceutical companies.
Clinical data and medical society presentations represent another significant news category. Esperion regularly presents analyses from the CLEAR Outcomes cardiovascular trial at major cardiology conferences, generating coverage when new data subsets demonstrate product benefits in specific patient populations or when medical guidelines incorporate bempedoic acid recommendations.
Financial updates including quarterly earnings reports and capital markets activities provide insight into the company's commercial progress and cash position. As a small-cap pharmaceutical company balancing commercial investment against revenue generation, these disclosures help investors track the trajectory toward sustainable profitability.
Pipeline developments appear periodically as Esperion advances preclinical candidates and evaluates new therapeutic applications for its scientific platform beyond cholesterol management. Bookmark this page to follow Esperion's progress across commercial execution, clinical evidence generation, and research advancement.
Esperion (NASDAQ: ESPR) reported a strong start in Q1 2022, with total revenue of $18.8 million, a 135% increase year-over-year. U.S. product revenue for NEXLETOL and NEXLIZET surged approximately 109% to $13.4 million. Retail prescription equivalents grew 56.7%. The CLEAR Outcomes Trial is nearing 95% MACE accumulation, with expectations for a topline readout in Q1 2023. Despite a net loss of $56.7 million, significantly reduced from $90.9 million in Q1 2021, the company maintains a solid financial outlook with $268.5 million in cash reserves.
Esperion (NASDAQ: ESPR) announced the publication of data from the CLEAR Harmony Open-Label Extension Study on bempedoic acid, demonstrating its long-term safety and efficacy in lowering LDL-C levels over 2.5 years. The study followed 1,462 patients, with results indicating sustained LDL-C reductions of -14.2% for previous bempedoic acid users and -15.0% for those switching from placebo. No new safety concerns emerged, although risks of hyperuricemia and tendon rupture were noted. Bempedoic acid is approved as an adjunct therapy for patients needing additional LDL-C reduction.
Esperion (NASDAQ: ESPR) announced the grant of 48,780 restricted stock units (RSUs) to 14 new employees on April 28, 2022. These RSUs are part of the 2017 Inducement Equity Incentive Plan, aimed at attracting individuals to the company. Each RSU will vest 25% after one year, with the remaining 75% vesting quarterly over three years, contingent on continued employment. This initiative underlines Esperion’s commitment to innovation in cholesterol management, particularly through its oral, once-daily non-statin LDL-cholesterol lowering drugs.
Esperion (NASDAQ: ESPR) has announced that its President and CEO, Sheldon Koenig, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022. The event is set to take place at 3:20 PM PT (6:20 PM ET) and will include both a presentation and individual meetings. Investors can access a live audio webcast through the company's website, with a replay available afterwards for 90 days. Esperion focuses on developing effective oral non-statin medications for cholesterol management, aiming to improve patient health outcomes.
Esperion (NASDAQ: ESPR) has appointed Stephen Rocamboli as a Class I director, filling a vacancy left by Dr. Mark McGovern’s retirement. Rocamboli, who has extensive experience in life sciences, is expected to enhance Esperion’s strategic direction as it commercializes its medicines and prepares for the upcoming CLEAR Outcomes trial readout in Q1 2023. CEO Sheldon Koenig expressed confidence in Rocamboli's contributions towards the commercialization of approved products and the development of new therapies.
Esperion (NASDAQ: ESPR) has announced the launch of the CLEAR ACS trial, aimed at evaluating the efficacy of NEXLIZET in reducing LDL-C in patients post-acute coronary syndrome (ACS). This 24-week study will recruit 500 patients, assessing the drug's safety and effectiveness in diverse, high-risk populations often underrepresented in clinical trials. The findings could significantly impact treatment protocols for LDL-C management. Key endpoints include changes in LDL-C levels and cardiovascular outcomes.
Esperion (NASDAQ: ESPR) plans to report its first-quarter 2022 financial results on May 3, 2022, before U.S. markets open. Following the announcement, management will discuss the results and business progress during a conference call at 8:00 a.m. ET. Interested parties can join the call by dialing (877) 831-3840 or (253) 237-1184, with an access code of 1489326. A live audio webcast will also be available on the Esperion website, along with a replay accessible two hours after the call.
Esperion has released positive pooled Phase 3 data demonstrating significant LDL-C reductions. Bempedoic acid monotherapy resulted in a 26.5% reduction versus placebo, while a fixed-dose combination of bempedoic acid and ezetimibe achieved a 39.2% reduction, both statistically significant (p<0.001). The study involved 427 participants, emphasizing lipid management for statin-intolerant patients. Ongoing trials like CLEAR Outcomes aim to enhance understanding of bempedoic acid’s efficacy. The findings suggest promise for patients unable to tolerate statins, marking a potential shift in cholesterol management strategies.
Esperion presented significant clinical analyses for NEXLETOL (bempedoic acid) at the ACC.22 conference, highlighting its efficacy in lowering LDL-C in patients with renal impairment and hypertension. The analyses, covering over 3,600 patients, demonstrated significant LDL-C reductions (p<0.0001) across various patient groups. NEXLETOL is the first oral, once-daily non-statin LDL-C-lowering medication approved by the FDA in nearly two decades, supporting its use for adults with established cardiovascular disease or heterozygous familial hypercholesterolemia who need additional LDL-C lowering.
Esperion (NASDAQ: ESPR) announced that President and CEO Sheldon Koenig will present at the 21st Annual Needham Healthcare Conference on April 12, 2022. The event will feature a virtual fireside chat and 1:1 meetings, starting at 9:30 a.m. ET. Interested parties can access live audio webcasts on the investor relations section of the Esperion website. Replays will be available for 90 days following the event. Esperion is focused on lipid management, developing innovative medicines to lower cholesterol.
FAQ
What is the current stock price of Esperion Therape (ESPR)?
What is the market cap of Esperion Therape (ESPR)?
